Thymoma versus thymic carcinoma: Differences in biology impacting treatment

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 5, 2013, Pages 577-583

  Kelly, Ronan J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOIMMUNE REGULATOR PROTEIN; BELINOSTAT; BEVACIZUMAB; CETUXIMAB; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; HISTONE DEACETYLASE INHIBITOR; NILOTINIB; SOMATOMEDIN C RECEPTOR; SORAFENIB; SUNITINIB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

CANCER CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER RESEARCH; CANCER STAGING; COMPARATIVE GENOMIC HYBRIDIZATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; ONCOGENE C KIT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; THYMOMA; THYMUS CANCER;

EID: 84877962047     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0073     Document Type: Review

References (39)

1. Engels EA. Epidemiology of thymoma and associated malignancies. J Thorac Oncol 2010;5(10 Suppl 4):S260-265.
2. Margaritora S, Cesario A, Cusumano G, et al. Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery. Ann Thorac Surg 2010;89:245-252; discussion 252.
3. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981;48:2485-2492.
4. Muller-Hermelink HK, Engel P, Kuo TT, et al. Tumours of the thymus. World Health Classification of Tumours, In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Pathology & Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press. 2004:146-248.
5. Chen G, Marx A, Chen WH, et al. New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. Cancer 2002;95:420-429.
6. Herens C, Radermecker M, Servais A, et al. Deletion (6)(p22p25) is a recurrent anomaly of thymoma: report of a second case and review of the literature. Cancer Genet Cytogenet 2003;146:66-69.
7. Kuhn E, Wistuba II. Molecular pathology of thymic epithelial neoplasms. Hematol Oncol Clin North Am 2008;22:443-455.
8. Okumura M, Fujii T, Shiono H, et al. Immunological function of thymoma and pathogenesis of paraneoplastic myasthenia gravis. Gen Thorac Cardiovasc Surg 2008;56:143-150.
9. Scarpino S, Di Napoli A, Stoppacciaro A, et al. Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. Clin Exp Immunol 2007;149:504-512.
10. Anderson MS, Venanzi ES, Chen Z, et al. The cellular mechanism of Aire control of T cell tolerance. Immunity 2005;23:227-239.
11. Burbelo PD, Browne SK, Sampaio EP, et al. Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia. Blood 2010;116:4848-4858.
12. Inoue M, Starostik P, Zettl A, et al. Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas. Cancer Res 2003;63:3708-3715.
13. Zettl A, Strobel P, Wagner K, et al. Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol 2000;157:257-266.
14. Inoue M, Marx A, Zettl A, et al. Chromosome 6 suffers frequent and multiple aberrations in thymoma. Am J Pathol 2002;161:1507-1513.
15. Girard N, Shen R, Guo T, et al. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res 2009;15:6790-6799.
16. Kelly RJ, Petrini I, Rajan A, et al. Thymic malignancies: from clinical management to targeted therapies. J Clin Oncol 2011;29:4820-4827.
17. Badve S, Goswami C, Gokmen-Polar Y, et al. Molecular analysis of thymoma. PLoS One 2012;7:e42669.
18. Pan CC, Chen PC, Chiang H. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol 2004;202:375-381.
19. Henley JD, Cummings OW, Loehrer PJ Sr. Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol 2004;130:222-224.
20. Strobel P, Hartmann M, Jakob A, et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 2004;350:2625-2626.
21. Yoh K, Nishiwaki Y, Ishii G, et al. Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer 2008;62:316-320.
22. Bisagni G, Rossi G, Cavazza A, et al. Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. J Thorac Oncol 2009;4:773-775.
23. Giaccone G, Rajan A, Ruijter R, et al. Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. J Thorac Oncol 2009;4:1270-1273.
24. Strobel P, Bargou R, Wolff A, et al. Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer 2010;103:196-200.
25. Yamaguchi H, Soda H, Kitazaki T, et al. Thymic carcinoma with epidermal growth factor receptor gene mutations. Lung Cancer 2006;52:261-262.
26. Suzuki E, Sasaki H, Kawano O, et al. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. Jpn J Clin Oncol 2006;36:351-356.
27. Ionescu DN, Sasatomi E, Cieply K, et al. Protein expression and gene amplification of epidermal growth factor receptor in thymomas. Cancer 2005;103:630-636.
28. Kurup A, Burns M, Dropcho S, et al. Phase II study of gefitinib treatment in advanced thymic malignancies [abstract]. J Clin Oncol 2005;23(Suppl): Abstract 7068.
29. Bedano PM, Perkins S, Burns M, et al. A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma [abstract]. J Clin Oncol 2008;26(Suppl):Abstract 19087.
30. Farina G, Garassino MC, Gambacorta M, et al. Response of thymoma to cetuximab. Lancet Oncol 2007;8:449-450.
31. Palmieri G, Marino M, Salvatore M, et al. Cetuximab is an active treatment of metastatic and chemorefractory thymoma. Front Biosci 2007;12:757-761.
32. Pan CC, Chen PC, Wang LS, et al. Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours. Histopathology 2003;43:165-172.
33. Cimpean AM, Raica M, Encica S, et al. Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus. Ann Anat 2008;190:238-245.
34. Sasaki H, Yukiue H, Kobayashi Y, et al. Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms. Surg Today 2001;31:1038- 1040.
35. Li XF, Chen Q, Huang WX, Ye YB. Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report. Med Oncol 2009;26:157- 160.
36. Steele NL, Plumb JA, Vidal L, et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 2008;14:804- 810.
37. Giaccone G, Rajan A, Berman A, et al. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol 2011;29:2052-2059.
38. Girard N, Teruya-Foldstein J, Payabyab EC, et al. Insulin-like growth factor-1 receptor expression in thymic malignancies. J Thorac Oncol 2010;5:1439-1446.
39. Zucali PA, Petrini I, Lorenzi E, et al. Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas. Cancer 2010;116:4686-4695.